Skip to main content
. Author manuscript; available in PMC: 2023 Feb 2.
Published in final edited form as: Mol Pharm. 2015 Feb 5;12(3):846–856. doi: 10.1021/mp500683c

Figure 4.

Figure 4.

Cytotoxicity of RAW264.7 incubated with hybrid vectors at various polymer doses formulated using (A) CPLA-26 and (B) CPLA-54 or (C) PEG-b-CPLA-20 and (D) PEG-b-CPLA-50. *Statistical significant (95% confidence) decreases in viability of CPLA-54 hybrids compared to CPLA-26 hybrids. @Statistical significance (95% confidence) compared to hybrid vector prepared using respective nonPEGylated CPLA polymer.